Publications (566) Publications auxquelles un chercheur a participé

2018

  1. Aligning digital CD8 + scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma

    Histopathology, Vol. 72, Núm. 2, pp. 270-284

  2. 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

    Movement Disorders, Vol. 33, Núm. 1, pp. 117-127

  3. 68Ga-PSMA PET/CT in prostate cancer

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 2, pp. 130-138

  4. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [ 18 F]FDG and sodium [ 18 F]fluoride PET

    BMC Cancer, Vol. 18, Núm. 1

  5. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus

    European Journal of Neurology, Vol. 25, Núm. 10, pp. 1201-1217

  6. TPEN exerts antitumor efficacy in murine mammary adenocarcinoma through an H 2 O 2 signaling mechanism dependent on caspase-3

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 18, Núm. 11, pp. 1617-1628

  7. A 60-Year-Old Male Smoker With Chronic Obstructive Pulmonary Disease and Hypereosinophilia

    Archivos de Bronconeumologia, Vol. 54, Núm. 7, pp. 394-395

  8. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

    Clinical Breast Cancer, Vol. 18, Núm. 4, pp. e613-e619

  9. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

    Cell, Vol. 175, Núm. 2, pp. 313-326

  10. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  11. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

    Nature Communications, Vol. 9, Núm. 1

  12. A multicentre, randomized controlled trial of telehealth for the management of COPD

    Respiratory Medicine, Vol. 144, pp. 74-81

  13. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients

    Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432

  14. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    Haematologica, Vol. 103, Núm. 9, pp. 1518-1526

  15. A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

    Haematologica, Vol. 103, Núm. 8, pp. 1351-1358

  16. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma

    Oncogene, Vol. 37, Núm. 27, pp. 3740-3752

  17. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  18. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

    Nature Communications, Vol. 9, Núm. 1

  19. Aberrant timing and oddball detection in Schizophrenia: findings from a signed differential mapping meta-analysis

    Heliyon, Vol. 4, Núm. 12

  20. Accuracy of a Laryngopharyngeal Endoscopic Esthesiometer (LPEER) for Evaluating Laryngopharyngeal Mechanosensitivity: A Validation Study in a Prospectively Recruited Cohort of Patients

    Dysphagia, Vol. 33, Núm. 1, pp. 15-25